Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction

Summary

Pregnancy-associated plasma protein A (PAPP-A) and matrix metalloproteinase 9 (MMP-9), both zinc-binding endopeptidases, are abundantly expressed in ruptured and eroded plaques in patients with acute coronary syndromes (ACS).The adhesion molecule CD-40 ligand (CD40L), expressed on activated platelets and T-lymphocytes, can activate metalloproteinases and thereby promote plaque-rupture. N-3 fatty acids, through their anti-inflammatory and anti-thrombotic properties,might reduce the levels of these proatherosclerotic markers and thereby the development of ACS. 300 patients were randomized on day4 to 6 following an acute myocardial infarction (MI) to receive either 4g of n-3 fatty acids or a similar daily dose of corn oil for at least one year.We compared levels of PAPP-A, MMP-9 and sCD-40 L at baseline and 12 months in each group, and also looked for inter-group changes. In the omega-3 group, the median level of PAPP-A rose from 0.47 mU/l to 0.56 mU/l (p < 0.001). In the same group, sCD-40 L decreased froma mean baseline value of 5.19 ng/ml to 2.45 ng/ml (p < 0.001) and MMP-9 decreased nonsignificantly from 360.50 ng/ml to 308.00 ng/ml. Corresponding values for the corn oil group were 0.54 mU/l to 0.59 mU/l for PAPP-A (p= 0.007), 5.27 ng/ml to 2.84 ng/ml for sCD-40 L (p< 0.001) and 430.00 ng/ml to 324.00 ng/ml for MMP-9 (p=ns), respectively. In conclusion; both interventions resulted in a significant rise in PAPP-A, a significant decrease in sCD40L and a non-significant decrease in MMP-9 after 12 months of treatment in MI survivors. No inter-group differences were noted.

Keywords

CD40-ligand - pregnancy associated plasma protein A (PAPP-A) - matrix metalloproteinase 9 (MMP-9) - acute myocardial infarction - N-3 fatty acids

• References

• 1 Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
• 2 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al. Membrane-associated CD40 and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.
• 3 Aggarwal A, Schneider DJ, Terrien EF. et al. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprite coronary plaques. AmJ Cardiol 2004; 93: 6-9.
• 4 Schönbeck U, Gerdes N, Varo N. et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106: 2888-93.
• 5 Schönbeck U, Mach F, Sukhova GK. et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells byT lymphocytes. Circ Res 1997; 81: 448-54.
• 6 Henn V, Slupsky JR, Grafe M. et al. CD40L on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 7 Aukrust P, Muller F, Ueland T. et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina Possible reflection of T-lymfocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-20.
• 8 Garlichs CD, John S, Schmeißer A. et al. Upregulation of CD40 and CD40 Ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 2001; 104: 2395-400.
• 9 Cipollone F, Mezzetti A, Porreca E. et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia Effects of statin therapy. Circulation 2002; 106: 399-402.
• 10 Schönbeck U, Varo N, Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
• 11 Varo N, de Lemos JA, Libby P. et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
• 12 Bayes-Genis A, Conover CA, Overgaard MT. et al. Pregnancy-associated plasma proteinA as a marker of acute coronary syndromes. N Eng J Med 2001; 345: 1022-9.
• 13 Torzewski M, Suriyaphol P, Paprotka K. et al. Enzymatic modification of low-density lipoprotein in the arterial wall A new role for plasmin and matrix metallo-proteinases in atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 2130-6.
• 14 Khosravi J, Diamandi A, Krishna R. et al. Pregnancy associated plasma protein-A: Ultrasensitive immunoassay and determination in coronary heart disease. Clinical Biochemistry 2002; 35: 531-8.
• 15 Laterza OF, Cameron SJ, Chappell D. et al. Evaluation of pregnancy-associated plasma protein-A as a prognostic indicator in acute coronary syndrome patients. Clin Chim Acta 2004; 348: 163-9.
• 16 Lund J, Qin QP, Ilva T. et al. Circulating pregnancyassociated proteinA predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924-6.
• 17 Kai H, Ikeda H, Yasukawa H. et al. Periferal blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
• 18 Bertsch T, Sueselbeck T, Wolpert C. et al. Time cource of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome. Clin Chem Lab Med 2005; 43: 660-3.
• 19 Tziakas DN, Chalikias GK, Parissis JT. et al. Serum profile of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes The effect of short-term atorvastatin treatment. Int J Cardiol 2004; 94: 269-77.
• 20 Zeng B, Prasan A, Fung KC. et al. Elevated circulating level of metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Int Med J 2005; 35: 331-5.
• 21 Tayebjee MH, Lip GYH, Tan KT. et al. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96: 339-45.
• 22 Tayebjee MH, Nadar S, Blann AD. et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase -1 in hypertension and their relationship to cardiovascular risk and treatment A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). AJH 2004; 17: 764-9.
• 23 Chen F, Erikson P, Hansson GK. et al. Expression of matrix metalloproteinase-9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med 2005; 15: 57-65.
• 24 Stulc T, Malbohan I, Malik J. et al. Increased levels of pregnancy associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. Am Heart J 2003; 146: e21.
• 25 Aso Y, Okumura K-I, Wakabayashi S. et al. Elevated pregnancy associated plasma protein-A in sera from type 2 diabetic patients with hypercholesterolemia:Association with carotid atherosclerosis and toe-brachial index. J Clin Endocrinol Metab 2004; 89: 5713-7.
• 26 Cosin-Sales J, Christiansen M, Kaminski P. et al. Pregnancy associated plasma protein-A and it`s endogenious inhibitor, the proform of eosinophil major basic protein (proMBP) are related to complex stenosis morphology in patients with stable angina pectoris. Circulation 2004; 109: 1724-8.
• 27 Zouridakis E, Avanzas P, Arroyo-Espliguero R. et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina. Circulation 2004; 110: 1747-53.
• 28 Blankenberg S, Rupprecht HJ, Poirier O. et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis in patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
• 29 Nilsen DWT, Albrektsen G, Landmark K. et al. Effects of a high dose concentrated n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001; 74: 50-6.
• 30 Kris-Etherton PM, Harris WS, Appel LJ. for the Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: e20-e31.
• 31 GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction; results of GISSIPrevenzion Trial. Lancet 1999; 354: 447-50.
• 32 He K, Song Y, Daviglus ML. et al. Accumulated evidence on fish consumption and coronary heart disease mortality A meta-analysis of cohort studies. Circulation 2004; 109: 2705-11.
• 33 Yzebe D, Lievre M. Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials. Fundam Clin Pharmacol 2004; 18: 581-92.
• 34 Calder PC. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 2005; 33: 423-7.
• 35 Monaco C, Andreakos E, Kiriakidis S. et al. Canonical pathway of nuclear factor ?B activation selectively regulated proinflammatory and prothrombotic respon-ses in human atherosclerosis. PNAS 2004; 101: 5634-9.
• 36 Weatherill AR, Lee JY, Zhao L. et al. Saturated and polyunsaturated fatty acids reciprocally modulate dendritic cell functions mediated through TLR41. J Immunol 2005; 174: 5390-7.
• 37 Suzuki I, Iigo M, Ishikawa C. et al. Inhibitory effects of oleic and docosahexanoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int J Cancer 1997; 73: 607-12.
• 38 Liu X-H, Rose DP. Suppression of type IV collagenase in MDA-MB-435 human breast cancer cells by eicosapentaenoic acid in vitro and in vivo . Cancer Letter 1995; 92: 21-6.
• 39 World Health Organisation. Myocardial infarction community registers. Copenhagen: World Health Organisation; 1976
• 40 Grundt H, Nilsen DWT, Mansoor MA. et al. Reduction in homocystein by n-3 polyunsaturated fatty acids (PUFAs) after 1 year in a randomised double-blind study following myocardial infarction No effect on endothelial adhesion properties. Pathophysiol Haemost Thromb 2003; 33: 88-95.
• 41 Grundt H, Hetland Ø, Nilsen DWT. Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high-doses of n-3 fatty polyunsaturated fatty acids. Thromb Haemost 2003; 89: 752-9.
• 42 Nordøy A, Bønaa KH, Nilsen H. et al. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidemia. J Int Med 1998; 243: 163-70.
• 43 Kim DN, Schmee J, Lee KT. et al. Hypo-atherogenic effect of dietary corn oil exceeds hypo-cholesterolemic effect in swine. Atherosclerosis 1984; 52: 101-13.
• 44 Wagner KH, Tomasch R, Elmadfa I. Impact of diets containing corn oil or olive/sunflower mixture on the human plasma and lipoprotein lipid metabolism. Eur J Nutr 2001; 40: 161-7.
• 45 McLennan PL, Abeywardena MY, Charnock JS. Reversal of the arrhythmogenic effect of long term saturated fatty acid intake by dietary n-3 and n-6 polyunsaturated fatty acids. Am J Clin Nutr 1990; 51: 53-8.
• 46 Schmidt EB, Varming K, Ernst E. et al. Dose-respons studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb Haemost 1990; 63: 1-5.
• 47 Qin Q-P, Laitinen P, Majamaa-Voltti K. et al. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002; 36: 358-61.
• 48 Apple FS, Wu AHB, Mair J. et al. on behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clinical Chemistry 2005; 51: 1-15.
• 49 Tziakas DN, Chalikias GK, Hatzinikolaou EI. et al. N-terminal Pro-B-type natriuretic peptide and matrix metalloproteinases in early and late ventricular remodelling after acute myocardial infarction. Am J Cardiol 2005; 96: 31-4.
• 50 Fialova L, Kalousova M, Soukupova J. et al. Relationship of pregnancy associated plasma protein-A to renal function and dialysis modalities. Kidney Blood Press Res 2004; 27: 88-95.